Newsletter | March 6, 2020

03.06.20 -- Considerations For Delivering Biologics To Market

Comparing Continuous And Batch Processing In Downstream Purification
Current continuous manufacturing technologies are being developed and implemented to manufacture a wide variety of products including monoclonal antibodies, recombinant proteins, and other biological modalities. Though upstream fed-batch and perfusion bioreactor unit processes are relatively mature, downstream process unit operations are less mature. In this case study, the productivity of purifications running in batch versus continuous mode are compared.
How To Address Process Characterization And Late-Phase Development Of A Monoclonal Antibody

Process characterization is an important step in the overall journey of product development. In this poster, scientists propose a stepwise approach for the definition and execution of process characterization for the production of a monoclonal antibody.

Novel Analytical Techniques For Monoclonal Antibodies

With the rising interest in biopharmaceuticals, drug developers need to quickly understand and evaluate the binding of therapeutic antibodies to Fc receptors. Learn how a new analytical testing panel that uses an Octet-based Fc receptor panel may help developers achieve a faster assessment of monoclonal antibody functionality — well before the final molecule is selected.

Catalent Biologics: Delivering Therapies To Market Faster
Catalent Biologics is your one integrated partner with expertise to get your biologics to market faster. We have the passion to help you accelerate, simplify, and de-risk your biologics from development and manufacturing, to fill/finish, clinical supply, and commercial launch.